

K060750

APR 19 2006

**510(K) SUMMARY OF SAFETY AND EFFECTIVENESS:**

Stryker® Injectable Cement

**General Information**

Proprietary Name:	Stryker® Injectable Cement
Common Name:	Hydroxyapatite Cement
Proposed Regulatory Class:	Class II
Device Classification:	NEA (21 CFR 872.3275) Cement, Ear, Nose and Throat FMF (21 CFR 880.5860) Syringe, Piston
Submitter:	Stryker® 4100 East Milham Avenue Kalamazoo, MI 49001 877-534-2464 x 4226
Submitter's Registration #:	8010177
Manufacturer's Registration #:	9610726
Contact Person:	Wade T. Rutkoskie Manager, Regulatory Affairs and Quality Assurance Phone: 877-534-2464 x 4226 Fax: 269-323-4215
Summary Preparation Date:	March 6, 2006

**Intended Use**

Stryker® Injectable Cement is indicated for use in the following: augmentation or coupling of the middle ear ossicles, attachment of the middle ear ossicles to middle ear implants, mechanical stabilization of middle ear prostheses, and the reconstruction of the posterior canal wall.

**Substantial Equivalency Information**

Stryker® Injectable Cement is substantially equivalent to legally marketed K060061 Stryker® Injectable Cement, K043334 Stryker® HAC Rapid Set Cement, and K042516 Walter Lorenz Otomimix.

	Stryker® Injectable Cement (PENDING)	K060061 Stryker Injectable Cement	K043334 Stryker® HAC Rapid Setting Cement	K 042561 Walter Lorenz Otomimix
<b>Intended Use:</b> Stryker® Injectable Cement is intended for use in the following: 1. Augmentation or coupling of the middle ear ossicles. 2. Attachment of the middle ear ossicles to middle ear implants. 3. Mechanical stabilization of the middle ear prostheses. 4. Reconstruction of the posterior canal wall.	√			√
<b>Material:</b> Calcium Phosphate	√	√	√	√
<b>Sterility:</b> Sterile	√	√	√	√
<b>Operational Principle:</b> Powder and liquid mixed to form a paste for application	√	√	√	√
<b>INJECTABLE Cement</b>	√	√		

The primary predicate device, Stryker Injectable Cement (K060061), is identical in material formulation, physical properties, chemical composition and performance. All predicate devices share the same operational principles and are provided sterile.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

APR 19 2006

Stryker®  
c/o Mr. Wade T. Rutkoskie  
750 Trade Centre Way  
Kalamazoo, MI 49001

Re: K060750

Trade/Device Name: Stryker® Injectable Cement  
Regulation Number: 21 CFR 872.3275  
Regulation Name: Cement, Ear, Nose and Throat  
Regulatory Class: Class II  
Product Code: NEA  
Dated: March 24, 2006  
Received: March 27, 2006

Dear Mr. Rutkoskie:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Wade T. Rutkoskie

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 827-8910. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "M B Eydelman, MD", with a stylized flourish at the end.

Malvina B. Eydelman, M.D.

Division Director

Division of Ophthalmic and Ear,

Nose and Throat Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510(K) Number (if known): K 060750

Device Name: Stryker® Injectable Cement

Indications for Use:

Stryker® Injectable Cement is indicated for use in the following: augmentation or coupling of the middle ear ossicles, attachment of the middle ear ossicles to middle ear implants, mechanical stabilization of middle ear prostheses, and the reconstruction of the posterior canal wall.

Prescription Use ✓  
(21 CFR 801 Subpart D)

AND/OR


Over-the-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Page \_\_\_ of \_\_\_

(Posted November 13, 2003)

  
(Division Sign-Off)  
Division of Ophthalmic Ear,  
Nose and Throat Devices  
510(k) Number K660750